FemmePharma, Inc. Release: Baltimore Native Returns To Her Roots Seeking Investors And Investigators For New Drug Protocol
Published: May 23, 2006
WAYNE, Pa., May 23 /PRNewswire/ -- FemmePharma Global Healthcare, Inc., a Philadelphia-area pharmaceutical company that focuses on developing treatments for diseases and disorders suffered by women, is reaching out to investors and investigators in the Baltimore area to discuss its new treatment for breast pain. The company recently was given permission by the FDA to open an Investigational New Drug (IND) Application to commence a Phase 2 clinical trial. FemmePharma president and CEO Gerianne Tringali DiPiano, who was born and raised in suburban Baltimore and is the daughter of an accomplished Baltimore-area entrepreneur, Joseph C. Tringali, is targeting the region because of the accelerated growth of bioscience companies and the state's increasingly favorable entrepreneurial climate. Now that the company's IND is open, clinical trials should begin by the fourth quarter of 2006 and the company will be seeking medical talent and subjects from Baltimore.
Maryland: A Biotech Industry Leader
"Maryland, and the Baltimore region specifically, are biotech hotspots offering an abundance of talent," stresses Tringali DiPiano. A 2004 study prepared by the Milken Institute ranked Maryland second in the nation for biopharmaceutical innovations. With more than 300 biotech companies and an annual payroll of $2.1 billion, Maryland is on the bioscience fast track. "I am confident that this region is the right place to begin clinical trials. As the epicenter of biotech activity, FemmePharma will have access to office space, laboratories, manufacturing, employees and expertise, factors that are critical to furthering FemmePharma's research interests," added Tringali DiPiano.
A Therapy to Improve Human Health
FemmePharma's foray into treating breast pain comes at the heels of the company's previous success at developing a treatment that lessens the severe discomfort caused by endometriosis. The treatment for endometriosis was developed from a unique, patented platform technology that eliminates systemic side effects by concentrating a small but effective amount of the drug directly to a targeted area of the disease or disorder.
The company is engineering its patented platform technology to develop a topical cream to treat breast pain that will eliminate the side effects caused by the few available treatments. "Physicians are limited in how they treat breast pain. They can prescribe an FDA-approved prescription medication that typically causes facial hair growth, weight gain and acne; or an over-the- counter pain reliever that does not address the underlying causes of breast pain," said Tringali DiPiano.
Breast Pain: A Common Problem
Breast pain is a widespread problem. Roughly 26 million women in the United States are plagued by the disorder, and about 15 percent of sufferers experience symptoms severe enough to warrant medication. Breast pain is debilitating and can cause its victims to miss work, withdraw from everyday activities, and recoil from intimacy. Sometimes the pain is so severe that a woman may even avoid hugging her children. But the condition is not always treated with concern. "Breast pain is sometimes diagnosed as phantom pain and is one of the leading reasons physicians over-prescribe mammography exams for young women," said Tringali DiPiano.
FemmePharma Global Healthcare's efforts to create an effective treatment that yields no harmful side effects could offer long-awaited relief for millions of women.
Founded by Gerianne Tringali DiPiano in 1996, FemmePharma Global Healthcare's goal is to develop safe and effective drugs that minimize or eliminate the side effects associated with existing drug therapies and ensuring that new therapies suit the female anatomy. The company has a proven track record. After successfully completing Phase 2 studies for its treatment of endometriosis, the product was acquired by KV Pharmaceutical, which will continue its development and bring the drug to market. Other current endeavors include a therapy to treat urinary incontinence in Phase 2 clinical trials, and products to treat dysmenorrhea and dysfunctional uterine bleeding in preclinical development.
For more information about the clinical trials in the Baltimore region, visit http://www.fpghc.com or call 610-995-0801 to obtain information.
CONTACT: Leza Raffel, +1-215-884-6499, for FemmePharma Global HealthcareFemmePharma Global Healthcare, Inc.
CONTACT: Leza Raffel, +1-215-884-6499, for FemmePharma Global Healthcare
Web site: http://www.fpghc.com/